Sidibé El Hassane
Centre médical Marc Sankalé, BP 5062, Fann Dakar, Sénégal.
Sante. 2007 Jan-Mar;17(1):51-5.
Various studies of medullary thyroid carcinoma have found its apoptosis rate to be very low. Tumor growth is usually progressive but in some cases, rapid progression and high proliferation are seen. Some mutations of the RET proto-oncogene are thought to have a direct or indirect effect on this clinical process. Five characteristics are significantly associated with poor survival: tumor necrosis, squamous histology, age older than 45 years, oxyphilic tumor cells together with a lack of intermediary cytoplasm cells, and finally, less than 50% of tumor cells immunoreactive to calcitonin. Although recent studies have identified the gene involved in this cancer, its molecular pathogenesis has not yet been elucidated. Medullary thyroid carcinoma is rare, but practitioners must be familiar with it because it presents specific therapeutic and diagnostic problems. Sensitive and specific direct genetic diagnosis of the principal mutation of the RET proto-oncongene is possible in patients with familial thyroid carcinoma or multiple endocrine neoplasia type 2. Screening is based on the immunoradiometric assay of calcitonin levels before and after pentagastrin stimulation in different populations: healthy subjects, persons with family members who have medullary thyroid carcinoma, patients with thyroid nodules or autoimmune chronic thyroiditis. Recently a somatic mutation on RET codon 918 was reported in patients with medullary thyroid carcinoma and those with C cell hyperplasia and multiple endocrine neoplasia together. This finding suggests that this particular mutation may play a role in tumorigenesis. Compared with patients with endocrine neoplasia syndromes type 2A and 2B, these patients appeared to have a syndrome clinically overlapping these, and its genetic basis may be distinct from them. Family members of patients with medullary thyroid carcinoma must be screened for this inherited disease. The mutations associated with medullary thyroid carcinoma and parathyroid tumors together appear to be closely related to the centromeric region of chromosome 10. At three months of age, Wag/Rij rats show hypersecretion under secretagogues and C cell hyperplasia; both signs are described as "pretumoral" in humans. A battery of markers are useful even though the gene for multiple endocrine neoplasia type 2 gene has recently been thought to be located in the pericentromeric region of chromosome 10 in white Europeans.
对甲状腺髓样癌的多项研究发现其凋亡率非常低。肿瘤生长通常呈进行性,但在某些情况下,可见快速进展和高增殖。RET原癌基因的一些突变被认为对这一临床过程有直接或间接影响。五个特征与预后不良显著相关:肿瘤坏死、鳞状组织学、年龄大于45岁、嗜酸性肿瘤细胞且缺乏中间细胞质细胞,以及最后,对降钙素免疫反应的肿瘤细胞少于50%。尽管最近的研究已经确定了与这种癌症相关的基因,但其分子发病机制尚未阐明。甲状腺髓样癌很罕见,但从业者必须熟悉它,因为它存在特定的治疗和诊断问题。对于患有家族性甲状腺癌或2型多发性内分泌腺瘤病的患者,对RET原癌基因的主要突变进行敏感且特异的直接基因诊断是可能的。筛查基于不同人群(健康受试者、有甲状腺髓样癌家族成员的人、甲状腺结节患者或自身免疫性慢性甲状腺炎患者)在五肽胃泌素刺激前后降钙素水平的免疫放射分析。最近,在甲状腺髓样癌患者以及同时患有C细胞增生和多发性内分泌腺瘤病的患者中报告了RET密码子918的体细胞突变。这一发现表明这种特定突变可能在肿瘤发生中起作用。与2A和2B型内分泌腺瘤综合征患者相比,这些患者似乎有一种临床症状与它们重叠的综合征,其遗传基础可能与它们不同。甲状腺髓样癌患者的家庭成员必须接受这种遗传性疾病的筛查。与甲状腺髓样癌和甲状旁腺肿瘤相关的突变似乎与10号染色体的着丝粒区域密切相关。在三个月大时,Wag/Rij大鼠在促分泌剂作用下出现分泌亢进和C细胞增生;这两种迹象在人类中都被描述为“肿瘤前”。尽管最近认为2型多发性内分泌腺瘤病基因位于白种欧洲人的10号染色体着丝粒周围区域,但一系列标志物仍然有用。